Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Laszlo

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Expert Opinion on Biological Therapy|March 7, 2014
Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilizationMassimo Martino, Daniele Laszlo, Francesco Lanza
Expert Opinion on Biological Therapy|October 16, 2014
Plerixafor: what we still have to learnFrancesco Lanza, Angelo Gardellini, Daniele Laszlo, et al.
Journal of Clinical Apheresis|January 21, 2021
Cost comparison of extracorporeal photopheresis technologies at the European Institute of OncologyAntonio Magarò, Bruno Lucchetti, Alessandro Caime, et al.
European Journal of Haematology|October 14, 2011
Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantationGiovanna Andreola, Aleksandra Babic, Cristina Rabascio, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 9, 2020
Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEOAlessandro Caime, Alessio Piredda, Bruno Lucchetti, et al.
Bone Marrow Transplantation|March 23, 2021
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysisCarlo Lazzaro, Luca Castagna, Francesco Lanza, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 16, 2013
Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case reportFederica Gigli, Angelo Gardellini, Aleksandra Babic, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|April 23, 2014
R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphomaJuan Montoro, Giovanna Andreola, Angelo Gardellini, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|April 7, 2012
Who should be really considered as a poor mobilizer in the plerixafor era?Giovanna Andreola, Anna Vanazzi, Davide Radice, et al.
Ecancermedicalscience|June 26, 2014
Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin's lymphoma for staging and treatment responseJuan Montoro, Daniele Laszlo, Natalia Pin Chuen Zing, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Expert Opinion on Biological Therapy|March 7, 2014
Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilizationMassimo Martino, Daniele Laszlo, Francesco Lanza
Expert Opinion on Biological Therapy|October 16, 2014
Plerixafor: what we still have to learnFrancesco Lanza, Angelo Gardellini, Daniele Laszlo, et al.
Journal of Clinical Apheresis|January 21, 2021
Cost comparison of extracorporeal photopheresis technologies at the European Institute of OncologyAntonio Magarò, Bruno Lucchetti, Alessandro Caime, et al.
European Journal of Haematology|October 14, 2011
Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantationGiovanna Andreola, Aleksandra Babic, Cristina Rabascio, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 9, 2020
Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEOAlessandro Caime, Alessio Piredda, Bruno Lucchetti, et al.
Bone Marrow Transplantation|March 23, 2021
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysisCarlo Lazzaro, Luca Castagna, Francesco Lanza, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 16, 2013
Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case reportFederica Gigli, Angelo Gardellini, Aleksandra Babic, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|April 23, 2014
R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphomaJuan Montoro, Giovanna Andreola, Angelo Gardellini, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|April 7, 2012
Who should be really considered as a poor mobilizer in the plerixafor era?Giovanna Andreola, Anna Vanazzi, Davide Radice, et al.
Ecancermedicalscience|June 26, 2014
Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin's lymphoma for staging and treatment responseJuan Montoro, Daniele Laszlo, Natalia Pin Chuen Zing, et al.
Pageof 5